PubRank

Julio Pow-Sang

Author PubWeight™ 36.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009 6.04
2 Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002 3.25
3 Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer 2005 1.65
4 Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006 1.45
5 Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology 2004 1.17
6 The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004 1.16
7 Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol 2006 1.09
8 Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer. J Urol 2003 1.08
9 Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol 2003 1.03
10 Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004 1.00
11 A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007 0.99
12 Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clin Med Urol 2008 0.99
13 Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002 0.96
14 Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev 2007 0.95
15 Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 2007 0.95
16 Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2004 0.88
17 Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 2008 0.88
18 Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer 2008 0.87
19 Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol 2009 0.87
20 Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials 2011 0.86
21 Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer 2007 0.86
22 Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol 2010 0.84
23 miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases. Asian J Androl 2013 0.84
24 Enrollment criteria controversies for active surveillance and triggers for conversion to treatment in prostate cancer. J Natl Compr Canc Netw 2012 0.81
25 Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin Exp Metastasis 2014 0.81
26 Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures. J Cancer Sci Ther 2012 0.81
27 A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy 2006 0.80
28 Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy 2012 0.79
29 Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology 2011 0.78
30 Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives. Am J Health Promot 2014 0.77
31 High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study. Cancer Lett 2012 0.75
32 Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol 2006 0.75